Clinical Development of a Therapeutic Agent for COPD

慢性阻塞性肺病治疗剂的临床开发

• 批准号: 8495831
• 负责人: Indu Parikh
• 金额: $ 100万
• 依托单位: BIOMARCK PHARMACEUTICALS, LTD
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-29 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8495831
• 关键词: Accounting; Air Pollution; Allergic rhinitis; Applications Grants; Architecture; Asthma; Books; Breathing; Bronchiectasis; Canis familiaris; Cause of Death; Cessation of life; Chronic; Chronic Bronchitis; Clinical; Clinical Research; Coughing; Cystic Fibrosis; Data; Development; Diagnosis; Disease; Dose; Double-Blind Method; Economic Burden; Epithelial Cells; Exertion; Funding; Gases; Grant; Howard Temin Award; Human; Impairment; Incidence; Individual; Inflammation; Inflammation Mediators; Lead; Lung; Lung diseases; MARCKS gene; Marketing; Medical; Morbidity - disease rate; Mucous body substance; Pathway interactions; Patient Care; Patients; Peptides; Pharmaceutical Preparations; Pharyngeal structure; Phase; Physiological; Placebos; Population; Preparation; Principal Investigator; Proteins; Provider; Pulmonary Emphysema; Rattus; Respiratory physiology; Rodent Model; Safety; Shortness of Breath; Site; Small Business Innovation Research Grant; Smoker; Symptoms; Therapeutic Agents; United States National Institutes of Health; Wheezing; Work; World Health Organization; aerosolized; airway inflammation; airway obstruction; base; cohort; effective therapy; inhibitor/antagonist; microbial alkaline proteinase inhibitor; mortality; novel; public health relevance; respiratory; safety study; social; therapeutic target

DESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a specific protein called MARCKS is a key molecule in the mucus secretary pathway. Based on this finding BioMarck developed a novel peptide, BIO-11006, which inhibited mucus hypersecretion as well as release of inflammatory mediators in human airway epithelial cells in culture and in various rodent models. BIO-11006, being a dual function inhibitor mucus secretion and inflammation, is an ideal drug to potentially treat various lung diseases including COPD. With funding from SBIR grants, BioMarck continued work on this project and has recently successfully completed, under an active IND, a 21-day proof-of-concept Phase 2A clinical study in 172 COPD patients suffering from chronic bronchitis with its lead compound BIO-11006. This SBIR Phase II Bridge grant application will allow BioMarck to undertake a 90-day Phase 2B multi center, double blind, dose selection clinical study with BIO-11006 with 300 COPD patients suffering from chronic bronchitis. A successful completion of the proposed project will allow BioMarck to select a dose level for the final Phase 3 clinical study. Worldwide the social and economic burden of COPD is enormous. COPD, being the 3th. leading cause of death, accounts for over 5 million deaths worldwide. Although there are more than 25 different drugs currently available in the market, the patients and the care providers are desperate for effective drugs for the treatment of COPD. BIO- 11006, by reducing both excess mucus and airway inflammation, has the potential to be a first in class drug to effectively treat this patien population.

描述（由申请人提供）：粘液分泌过多进入呼吸道是几种肺部疾病的主要因素，包括慢性肺病（COPD）、哮喘、囊性纤维化、过敏性鼻炎和支气管扩张。尽管具有明显的医学重要性，但目前还没有有效的治疗方法来控制这些疾病的过量粘液分泌，并且很少有潜在的治疗靶点。我们发现一种叫做MARCKS的特殊蛋白质是粘液分泌途径中的关键分子。基于这一发现，biomck开发了一种新的肽BIO-11006，可以抑制培养和各种啮齿动物模型中人气道上皮细胞的粘液分泌和炎症介质的释放。BIO-11006是一种具有粘液分泌和炎症双重功能的抑制剂，是潜在治疗包括COPD在内的多种肺部疾病的理想药物。在SBIR的资助下，生物标志物继续开展该项目，并于最近成功完成了一项为期21天的2A期临床研究，该研究以其先导化合物BIO-11006在172名慢性支气管炎COPD患者中进行。这项SBIR II期桥梁拨款申请将允许生物标志物进行为期90天的2B期多中心、双盲、剂量选择临床研究，使用BIO-11006治疗300名慢性支气管炎患者。该项目的成功完成将允许生物标记公司为最终的3期临床研究选择一个剂量水平。在世界范围内，慢性阻塞性肺病的社会和经济负担是巨大的。COPD，排在第三位。这是主要的死亡原因，在全世界造成500多万人死亡。尽管目前市场上有超过25种不同的药物可供使用，但患者和护理提供者迫切需要治疗COPD的有效药物。BIO- 11006通过减少多余的粘液和气道炎症，有可能成为有效治疗这一患者群体的一流药物。